Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1].
[1]. Glenmark's molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials.
















